Avanir Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$6.6Mgeneral payments (2019-2025)
$138Kresearch payments (2019-2025)
20,308clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Kenneth Colley | San Francisco, CA | Internal Medicine | $386,161.86 |
| Adam Sky | Saint Louis, MO | Psychiatry | $344,354.03 |
| Amita Patel | Dayton, OH | Psychiatry | $309,459.12 |
| Charles Nevels | Tuscaloosa, AL | Geriatric Psychiatry | $247,714.50 |
| Jason Caplan | Phoenix, AZ | Psychiatry | $238,159.26 |
| Vadim Baram | Saint Louis, MO | Psychiatry | $189,070.10 |
| Jeffrey Kittrelle | San Diego, CA | Clinical Pharmacology | $181,200.00 |
| Syed Asad | Jacksonville, FL | Neurology (Psychiatry & Neurology) | $169,551.78 |
| Parikshit Deshmukh | Ocala, FL | Psychiatry | $158,053.71 |
| Steven Fogelman | Rome, NY | Psychiatry | $146,752.42 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.